Assessment of the effect of vitamin E supplementation on the ocular tear film
| ISRCTN | ISRCTN39888829 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN39888829 |
| Sponsor | King Saud University |
| Funder | College of Medicine, King Saud University |
- Submission date
- 29/09/2026
- Registration date
- 01/10/2026
- Last edited
- 01/10/2026
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Gamal El-Hiti
Scientific, Public, Principal investigator
Scientific, Public, Principal investigator
Department of Optometry, College of Applied Medical Sciences, King Saud University
Riyadh 11433
P.O. BOX 10219
Saudi Arabia
| 0000-0001-6675-3126 | |
| Phone | +966 0114693778 |
| gelhiti@ksu.edu.sa |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | Non-randomized controlled trial |
| Masking | Blinded (masking used) |
| Control | Placebo |
| Assignment | Parallel |
| Purpose | Basic science |
| Participant information sheet | 50368_PIS.pdf |
| Scientific title | Potential benefits of short-term vitamin E supplementation for the ocular tear film: A randomized controlled trial |
| Study acronym | VIT-E |
| Study objectives | Randomized controlled trial |
| Ethics approval(s) |
Approved 24/11/2025, Institutional Review Board (IRB) at King Saud University (Health Sciences Colleges Researches on Human Subjects, King Saud University, Riyadh, 11461, Saudi Arabia; +966 0114691529; fbashiri@ksu.edu.sa), ref: E-25-10201 |
| Health condition(s) or problem(s) studied | Impact of vitamin E on the ocular tear film |
| Intervention | Participants will receive oral vitamin E supplementation consisting of one JP Natural Vitamin E 400 IU softgel capsule (containing 268 mg natural alpha-tocopherol) taken once daily for three consecutive days. Baseline assessments will be conducted before supplementation and will include completion of the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire and tear film evaluations comprising non-invasive tear breakup time (NITBUT), tear meniscus height (TMH), and tear ferning (TF) tests. Participants will attend a follow-up visit 24 hours after the third vitamin E dose, during which the SPEED questionnaire and all tear film assessments will be repeated to evaluate changes in subjective symptoms of ocular dryness and objective tear film parameters. The control group will receive placebo capsules for comparison, and we will obtain measurements on days 1 and 4. |
| Intervention type | Supplement |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) | |
| Completion date | 30/03/2026 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 27 Years |
| Sex | All |
| Target sample size at registration | 64 |
| Total final enrolment | 64 |
| Key inclusion criteria | 1. Healthy adults without eye diseases or disorders 2. Individuals who do not wear contact lenses 3. Have not undergone ocular surgery 4. Do not have high blood pressure |
| Key exclusion criteria | Not meeting the key inclusion criteria |
| Date of first enrolment | 06/01/2026 |
| Date of final enrolment | 26/03/2026 |
Locations
Countries of recruitment
- Saudi Arabia
Study participating centres
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | 30/09/2026 | No | Yes | ||
| Protocol file | 01/10/2026 | No | No | ||
| Statistical Analysis Plan | 01/10/2026 | No | No |
Additional files
- 50368_PIS.pdf
- Participant information sheet
- 50368_Protocol.pdf
- Protocol file
- 50368_Protocol.pdf
- Statistical Analysis Plan
Editorial Notes
30/09/2026: Study’s existence confirmed by the King Saud University Medical City, Institutional Review Board (IRB), Human Subject Researches.